Exhibit 99.1
TScan Therapeutics Announces Transition of Chief Financial Officer
WALTHAM, Mass., June 29, 2023 TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on
the development of T cell receptor (TCR)-engineered T cell therapies (TCR-Ts) for the treatment of patients with cancer, today announced that its Chief Financial Officer, Brian M. Silver, J.D., will be leaving
the Company, effective July 21, 2023, to pursue a new opportunity at a leading advisory firm based in New York, where he lives with his family. Brian will continue to be available to provide strategic advice for the Company. The Company has
initiated a search for a successor chief financial officer.
We extend our sincere thanks to Brian for his important contributions since joining the
Company and wish him well in his new endeavor, said Gavin MacBeath, Ph.D., Chief Executive Officer. Brians extensive experience in biotechnology executive leadership roles has been crucial in ensuring the financial strength of the
Company and has allowed him to contribute to the advancement of our strategy and clinical programs. We are pleased that Brian will be able to continue his relationship with TScan by providing strategic advice, as his expertise, knowledge, vision,
energy, and passion have proven invaluable to our Company.
It has been a privilege working initially as a board member and then as an
executive with my colleagues at TScan. I am proud to have helped TScan grow from a preclinical platform company to a fully integrated research, development and manufacturing organization working to improve the lives of patients with cancer and
autoimmune disease through the development of advanced cell therapies. I look forward to continuing to provide strategic input to TScan in the future, said Mr. Silver. With the proceeds of our convertible note with K2, the Amgen
research partnership and our follow-on financing, I am confident that TScan has the financial capability to execute on our significant clinical milestones into 2026.
About TScan Therapeutics, Inc.
TScan is a clinical-stage
biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Companys lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to
eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid
tumors. The Company has developed and continues to build its ImmunoBank, the Companys repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to,
express or implied statements regarding the Companys plans, progress, and timing relating to the Companys solid tumor programs and the presentation of data, the Companys current and future research and development plans or
expectations, the structure, timing and success of the Companys planned preclinical development, submission of INDs, and clinical trials, the potential benefits of any of the